Nebacumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458283142

| image =

| type = mab

| mab_type = mab

| source = u

| target = endotoxin

| tradename =

| Drugs.com = {{drugs.com|international|nebacumab}}

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 138661-01-5

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 908FWN27WK

| ATC_prefix = J06

| ATC_suffix = BC01

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D05126

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.{{cite journal | vauthors = Derkx B, Wittes J, McCloskey R | title = Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group | journal = Clinical Infectious Diseases | volume = 28 | issue = 4 | pages = 770–7 | date = April 1999 | pmid = 10825037 | doi = 10.1086/515184 | doi-access = free }} It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[https://web.archive.org/web/20091107133217/http://apps.who.int/medicinedocs/en/d/Js4902e/4.1.262.html#Js4902e.4.1.262 WHO: Consolidated List of Products]